International Trade Commission May 22, 2015 – Federal Register Recent Federal Regulation Documents

Certain Recombinant Factor VIII Products; Institution of Investigation
Document Number: 2015-12390
Type: Notice
Date: 2015-05-22
Agency: International Trade Commission, Agencies and Commissions
Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on April 16, 2015, under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, on behalf of Baxter International Inc. of Deerfield, Illinois; Baxter Healthcare Corporation of Deerfield, Illinois; and Baxter Healthcare SA, of Switzerland. Letters supplementing the complaint were filed on April 21, 2015; May 1, 2015; and May 4, 2015. The complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain recombinant factor VIII products by reason of infringement of certain claims of U.S. Patent No. 6,100,061 (``the '061 patent''); U.S. Patent No. 6,936,441 (``the '441 patent''); and U.S. Patent No. 8,084,252 (``the '252 patent''). The complaint further alleges that an industry in the United States exists as required by subsection (a)(2) of section 337. The complainants request that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.